Filing summary
Entity and period: The supplied filing is Aquinox Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2018. It is not a Neurogene Inc. filing, despite the request metadata. Financial amounts below are in U.S. dollars; monetary figures are in millions unless stated otherwise.
Business context and key financial metrics
Aquinox was a clinical-stage pharmaceutical company developing rosiptor, an oral SHIP1 activator, for interstitial cystitis/bladder pain syndrome (IC/BPS). It reported no revenue and no approved products.
| Metric | Q1 2018 | Q1 2017 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $10.5 | $5.8 |
| General and administrative expense | $4.3 | $2.7 |
| Total operating expenses | $14.8 | $8.5 |
| Other income, net | $0.2 | $0.2 |
| Net loss | $14.6 | $8.3 |
| Net loss per share, basic and diluted | $0.62 | $0.36 |
| Cash used in operating activities | $15.6 | $11.3 |
R&D growth primarily reflected increased activity in the Leadership 301 Phase 3 trial. G&A increased mainly from personnel costs and pre-commercial and market-assessment activity. The filing does not present a gross margin or operating margin; with no revenue, the company remained loss-making.
At March 31, 2018, cash and cash equivalents were $66.6 and short-term investments were $26.1, totaling $92.7 in cash, equivalents and investments. Working capital was $84.9. Total liabilities were $9.8, including $0.03 of capital lease obligations and $0.4 of deferred rent; the filing reports no material borrowing debt. Accumulated deficit was $213.1. The company said existing resources were expected to fund operations for at least 12 months, while anticipating a need for substantial additional financing in the future.
Cash and cash equivalents increased $14.6 during the quarter, chiefly because $30.0 of investments matured; this was a conversion of investments to cash, not operating cash generation. Short-term investments fell from $56.1 at year-end to $26.1 at quarter-end.
Material changes versus the prior comparable period
- Net loss increased by $6.3, and loss per share rose from $0.36 to $0.62.
- Total operating expenses rose by $6.3 (about 74%); R&D increased about 82% and G&A about 57%.
- Operating cash use increased by $4.3. Cash and equivalents were higher than at year-end 2017, largely due to investment maturities; total cash, equivalents and short-term investments were $92.7.
- Stock-based compensation expense increased to $1.3 from $0.6. The company granted 787,490 options during the quarter.
Outlook, risks and other notable items
- Management anticipated Leadership 301 top-line data in the third quarter of 2018. The trial enrolled 341 women and 92 men and compared once-daily 100 mg and 200 mg rosiptor with placebo; the primary endpoint focused on change in maximum daily bladder pain at week 12 in female participants.
- Management was discussing regulatory requirements with the FDA and other authorities and evaluating additional trials needed to support a potential application. The number, design and scale of further trials—and resulting costs and timing—were not settled.
- The company expected losses and operating expenses to continue increasing. Additional capital could be required sooner than anticipated; financing might be unavailable or cause dilution, impose debt restrictions, or require licensing rights on unfavorable terms.
- Material development risks include uncertain Phase 3 efficacy and safety, the unvalidated SHIP1 target, possible additional trial requirements, regulatory uncertainty, trial execution and enrollment delays, and reliance on third-party research and manufacturing providers. Earlier rosiptor trials in other indications had not demonstrated efficacy; the filing also disclosed animal toxicities, including gastrointestinal ulceration and ocular lens effects, while reported clinical side effects were generally mild gastrointestinal symptoms.
- The company had no commercial infrastructure and no commercialization collaboration in place. Its rosiptor patents were described as running through 2024 in Europe and 2028 in the United States, subject to possible extensions.
- Foreign-currency exposure was not hedged. Management estimated that a hypothetical 100-basis-point interest-rate increase would reduce investment fair value by $0.04.
- Management reported disclosure controls effective at a reasonable assurance level and no material change in internal control over financial reporting. It reported no off-balance-sheet arrangements and no material changes in contractual commitments from the 2017 Form 10-K.
- After quarter-end, Chief Commercial Officer and U.S. Business Head Abigail Jenkins gave notice of resignation for family reasons, effective May 11, 2018; the company planned to recruit a replacement.
Important facts for investors to verify
- Confirm the filing identity: the supplied 10-Q belongs to Aquinox Pharmaceuticals, Inc., not Neurogene Inc.
- Check Leadership 301 top-line results and subsequent regulatory feedback, including whether further trials are required.
- Assess the trial’s safety findings and whether the animal toxicities or other adverse events affect development.
- Track cash burn, the stated 12-month funding estimate, and any subsequent financing or dilution.
- Review the commercial leadership transition, manufacturing capacity and dependence on single-source contract manufacturers.